Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
तुलना करने के लिए मीट्रिक्स | AZTR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधAZTRपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.2x | −2.4x | −0.5x | |
PEG अनुपात | 0.00 | 0.14 | 0.00 | |
क़ीमत/बुक | 0.9x | 2.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 8.1x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 81.5% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.8% | 6.1% | अनलॉक करें |